NEW YORK (GenomeWeb) – T2 Biosystems today set a price range of between $15 and $17 per share on its planned initial public offering, with anticipated net proceeds of up to $65.9 million.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission, the molecular diagnostics firm said it plans to offer 4 million shares of its common stock. At the $16 midpoint price, the offering would bring in net proceeds of $57 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.